is euphoric
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Bingo! The only good think about Sandy is that one day he will die and hopefully it will be a long dragged out painful one from a nice horrible disease. He is the filth of the earth.
Sandy? isn't he that Canadian punk that ripped off...err...allegedly RIPPED Off many of millions of dollars through MANY MANY scams? No reverse splits! LOL BKMPP? LOLOLOL
Long Live Sandy???? LOLOLOLOLOLOL That gave me a good laugh!
trotted? No I am a realistic person who is not a short and knows the damaged Sandy winick has caused and his guilty buddies. Time will tell. There is nothing behind this symbol. no company, no leader, no NOTHING. The "entity" is no more.
FDA approval will make people look harder. 2 drugs in Phase 3. Hoping for the best!
Great guys and companies with real potential.
http://www.huffingtonpost.ca/2013/12/31/sandy-winick-gregory-curry_n_4525076.html
no flame here with tgln. The lights went out many years ago.
My fellow Doe, there is only so much we can do. People will have to learn from their OWN mistakes. Been there, done that too many times to admit that I am ashamed. But with THIS one, I was sued! That was a good one!
LOL. That knucklehead was ranting about some BS stock holdings and how big news was coming. Well here IS the big news! Thanks Renee for making me laugh on this one! LOL
Good Ole Sandy Winnick
That is HYSTERICAL!!!!!!!!!!!!!!!
Santa has plenty of coal for this POS
So I walked into my house today and thought I had stepped in a dog BM. I checked both shoes and they were clean. I sniffed around and then found my KaTrillion shares of BKMPP and my statement showing BKMP shares and realized although I had not stepped in a dog BM, I had that big pile of BM still in my house.
Here is a nice read of the one who attempted to destroy the fine Doe name:
http://www.securitieslawyer101.com/2014/attorney-kenneth-eade-barred-from-practicing-before-the-sec/
WOW, $1100 in trades. This is soooo exciting I can barely sleep! Just the beginning of the rebirth of...ummm...what does this company do now and where are they and who is in charge? oh, but I am exciting!
"The Best Jerry...The Best!"
3 share -nothing +something? goony goo googus?
you can have fun and buy tbcglobalnews.com for $280 from big yacht company.
website for sale on big company. big ownership of nothing so sell website identity.
good lucks for you -nothing=something in nowhere
I would expect nothing less from this SUPERB multi-national corporation with such an amazing leader Sandy Winnnnick.
OH YEAH! Back up the bus and load the rocket!! LOL it will Fly just like that new Virgin aircraft!
WOW! It's like really cool! Samai Singjan is such a cool guy!! phone number belongs to a Charles T in MS. Kolt Holt is a great transfer agent as well!!! AND the website is VERY informative! Great information posted! that helps ANYBODIES DD on this hot Mess!
Thanks!!
Load up on shares and back up the bus and the rocket is ready to take off? I guess the pumping bus and rocket are out of fuel because the company has no more money left. Must be that BIG investment into the Disney of the Catskills! LOL Newsanyday? I know a guy who told me? I think NOT!!
LOLOL
A. WHO cares how the alledged SCAMMER's name is spelled? Petty nonesense! I have a 4 letter word for how is SHOULD be spelled. and your Saviours name is spelled with ONE N
B. Do you realize it is not the Rag Star from the US, but the TORONTO STAR? The largest circulated paper in Canada?
C. Why defend something like Winick when he has been such a low life, with a history of scamming, bribing and being a basic piece of garbage?!
D. Why when anybody says anything truthful that is also negative about a POS nothing of a sub sub sub crap penny stock, they are accused of being a shorter? 4 million shares traded since june (OR $400!)
E. I thought you were ignoring me so why respond? LOL Guess you love His life so much that you feel the need to respond and defend a criminal.
A. The other Canadians charged are Sandy Winick, Greg Curry, and his son Kolt Curry. All are in jail in the U.S. awaiting trial. Winick and Greg Curry were arrested by FBI agents in Thailand last summer after initially evading authorities.
http://www.thestar.com/business/2014/03/28/ontario_judge_signs_us_extradition_order_for_alleged_fraudster.html
B. A Basher on a .00000001 stock with no company, product of CEO behind it? Good One! LOL
C. LOLOLOLOLOLOLOLOLOLOLOLOL Dream...Dream, Dream, Dream, Dream, Dreammmmm
I know you are "Ignoring" me, but if you read ANYTHING on this site, you would have read that the trial is set for Trial 6/1/15 at 9:00 a.m.
I posted the info below so you do not need to search.
http://www.justice.gov/usao/nye/vw/PendingCases/CR-13-0452%20%20SANDY%20WINICK%20et%20al%20Court%20events.pdf
http://www.justice.gov/usao/nye/vw/PendingCases/CR-13-0452%20-%20Superseding%20Indictment%201%20U.S.%20v.%20SANDY%20WINICK%20et%20al.pdf
Figures with Fleming that his new "venture" would be associated with Food.
PARIS and THE WOODLANDS, Texas, Oct. 22, 2014 /PRNewswire/ -- Ipsen (Euronext: IPN; ADR: IPSEY) and Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that they have entered into an exclusive licensing agreement for Ipsen to commercialize telotristat etiprate outside of North America and Japan, with a focus on the treatment of carcinoid syndrome. Lexicon retains sole rights to commercialize telotristat etiprate in the United States, Canada and Japan.
Lexicon is conducting Phase 3 clinical trials of telotristat etiprate for carcinoid syndrome, a serious condition caused by symptomatic neuroendocrine tumors, which produce large amounts of serotonin. Carcinoid syndrome is characterized by severe diarrhea, flushing and, in some cases, heart valve damage. Telotristat etiprate is an oral, small-molecule inhibitor of tryptophan hydroxylase (TPH) that reduces peripheral serotonin production without affecting brain serotonin levels. Telotristat etiprate has received fast track status and orphan drug designation from the Food and Drug Administration in the United States, and has received orphan drug designation from the European Medicines Agency.
Lexicon will continue to lead the global Phase 3 clinical program for telotristat etiprate in carcinoid syndrome, from which data are expected in 2015. The pivotal Phase 3 trial is comparing telotristat etiprate to placebo on a background of somatostatin analog (SSA) therapy, the current standard of care, in patients whose carcinoid syndrome is not adequately controlled with lanreotide or octreotide. The clinical Phase 3 study is recruiting in approximately 70 centers worldwide. Lexicon will continue to be responsible for the potential registration of telotristat etiprate in the U.S., Canada and Japan, while Lexicon and Ipsen will collaborate to seek regulatory approvals in Europe and other countries within the Ipsen licensed territory, with Ipsen assuming the lead responsibility in those markets.
"This collaboration with Ipsen provides the opportunity to create added value for Lexicon and more effectively commercialize telotristat etiprate in markets around the world," said Lonnel Coats, Lexicon's President and Chief Executive Officer. "Ipsen is a leader in the treatment of carcinoid syndrome and neuroendocrine tumors with Somatuline® (lanreotide). Lexicon will benefit commercially from Ipsen's substantial market presence in Europe and other countries in the licensed territory, and will benefit globally from coordination with Ipsen on medical and scientific matters. This agreement represents an important achievement for Lexicon as we continue to execute on a strategy to translate our discoveries into life-changing products for patients in important areas of unmet medical need."
Marc de Garidel, Chairman and Chief Executive Officer of Ipsen stated: "Ipsen is delighted to enter into a partnership with Lexicon in Europe and other countries. The CLARINET® study with Somatuline® (lanreotide) paved the way for a change in the treatment paradigm for pancreatic and gastro intestinal NET patients. Upon approval, telotristat etiprate will enlarge our footprint in the symptomatic management of NET and offer important benefits to patients with carcinoid syndrome." Marc de Garidel added: "This agreement reflects our strategy to strengthen our presence in the fields of oncology, endocrinology and neurology, which will continue to be supported by our newly signed five-year multi-currency €500 million revolving credit facility."
Under the financial terms of the agreement, Lexicon is eligible to receive up to $145 million, comprised of a $23 million upfront payment and additional payments contingent upon achievement of clinical, regulatory and commercial milestones. In addition, Lexicon is also eligible to receive royalties on net sales of telotristat etiprate in the licensed territory.
About carcinoid syndrome
Neuroendocrine neoplasms are tumors arising from the diffuse neuroendocrine system most often along the gastrointestinal tract. They are rare but their incidence is increasing (approximately 2.5 to 4.5 new cases diagnosed per 100,000 persons per year). They constitute a heterogeneous group of tumors with location of the primary tumor in the gastric mucosa, pancreas, small and large intestine. As a result of their origin, they are capable of releasing a variety of hormones and neuroamines, most commonly serotonin, which, when released into the systemic circulation, can cause distinct clinical symptoms, such as the carcinoid syndrome associating diarrhea and flushing, with often abdominal pain. In some cases, digestive disorders and flushing are associated with heart failure (wheezing, edema of the lower limbs, irregular heartbeats) indicator of carcinoid valvular heart disease.
Lexicon Conference Call
Lexicon management will hold a conference call at 8:30 a.m. Eastern Time on October 22, 2014. The dial-in number for the conference call is 888-645-5785 (within the US/Canada) or 970-300-1531 (international). The conference ID for all callers is 11632. Investors can access a live webcast of the call at www.lexpharma.com. An archived version of the webcast will be available on the website through November 22, 2014.
About Lexicon
Lexicon is a biopharmaceutical company focused on developing breakthrough treatments for human disease. Lexicon has clinical-stage drug programs for diabetes, carcinoid syndrome, and other indications, all of which were discovered by Lexicon's research team. Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets. For additional information about Lexicon and its programs, please visit www.lexpharma.com.
About Ipsen
Ipsen is a global specialty-driven pharmaceutical company with total sales exceeding €1.2 billion in 2013. Ipsen's ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its development strategy is supported by 3 franchises: neurology, endocrinology and uro-oncology. Moreover, the Group has an active policy of partnerships. Ipsen's R&D is focused on its innovative and differentiated technological platforms, peptides and toxins. In 2013, R&D expenditure totaled close to €260 million, representing more than 21% of Group sales. Moreover, Ipsen also has a significant presence in primary care. The Group has close to 4,600 employees worldwide. Ipsen's shares are traded on segment A of Euronext Paris (stock code: IPN, ISIN code: FR0010259150) and eligible to the "Service de Règlement Différé" ("SRD"). The Group is part of the SBF 120 index. Ipsen has implemented a Sponsored Level I American Depositary Receipt (ADR) program, which trade on the over-the-counter market in the United States under the symbol IPSEY. For more information on Ipsen, visit www.ipsen.com.
Lexicon Forward Looking Statements
This press release contains "forward-looking statements," including statements relating to Lexicon's clinical development of telotristat etiprate, characterizations of the results of and projected timing of clinical trials of telotristat etiprate, and the potential therapeutic and commercial potential of telotristat etiprate. The press release also contains forward-looking statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to meet its capital requirements, successfully conduct clinical development of telotristat etiprate and preclinical and clinical development of its other potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2013, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.
Ipsen Forward Looking Statements
The forward-looking statements, objectives and targets contained herein are based on the Group's management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. All of the above risks could affect the Group's future ability to achieve its financial targets, which were set assuming reasonable macroeconomic conditions based on the information available today. Use of the words "believes," "anticipates" and "expects" and similar expressions are intended to identify forward-looking statements, including the Group's expectations regarding future events, including regulatory filings and determinations. Moreover, the targets described in this document were prepared without taking into account external growth assumptions and potential future acquisitions, which may alter these parameters. These objectives are based on data and assumptions regarded as reasonable by the Group. These targets depend on conditions or facts likely to happen in the future, and not exclusively on historical data. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties, notably the fact that a promising product in early development phase or clinical trial may end up never being launched on the market or reaching its commercial targets, notably for regulatory or competition reasons. The Group must face or might face competition from generic products that might translate into a loss of market share. Furthermore, the Research and Development process involves several stages each of which involves the substantial risk that the Group may fail to achieve its objectives and be forced to abandon its efforts with regards to a product in which it has invested significant sums. Therefore, the Group cannot be certain that favourable results obtained during pre-clinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the product concerned. There can be no guarantees a product will receive the necessary regulatory approvals or that the product will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Other risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the Group's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Group's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. The Group also depends on third parties to develop and market some of its products which could potentially generate substantial royalties; these partners could behave in such ways which could cause damage to the Group's activities and financial results. The Group cannot be certain that its partners will fulfil their obligations. It might be unable to obtain any benefit from those agreements. A default by any of the Group's partners could generate lower revenues than expected. Such situations could have a negative impact on the Group's business, financial position or performance. The Group expressly disclaims any obligation or undertaking to update or revise any forward looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable law. The Group's business is subject to the risk factors outlined in its registration documents filed with the French Autorité des Marchés Financiers.
SOURCE Lexicon Pharmaceuticals, Inc.
http://www.prnewswire.com/news-releases/lexicon-and-ipsen-enter-into-ex-north-americajapan-licensing-and-commercialization-agreement-for-telotristat-etiprate-900343730.html
Yeah big real estate deal purchased with worthless paper and built with more worthless paper. Oh and I heard that from a friend of a cousins dry cleaner so it must be true!
also could be those feabily pumping IFLM do not have time for this POS right now. oh but they will be back for sure.
Reliable source told me, cousin of a friend who lives down the block from the CEO's maid's dog walker, that nothing is happening as always. Hilltop is a dream as was SIIR and the rest of the garbage this company has spewed.
oh and I forgot this my fellow Doe, Their corporate office is a Regus rental office/mailbox in Manhattan.
LOL it is funny how there is always a "reliable source" with sub penny nothing stocks. Zero money in the bank account, market cap of 265,316 , hundreds of thousands of share to flood the market with on feeble pumps, and they will make a land deal? LOL, now that is funny!
For years this company has owned and leased mine sites. I researched and could not find any actual gold, copper, etc produced. Could somebody please lead me to somewhere on their website that shows actual production?
TIA
Thanks. I appreciate your feedback and info. GLTY
Will the shares held by BOD be diluted or able to be sold at the new R/S pricing?
Also A/O Mar 2014 was a 40+ million net loss since inception?
Have the produced any lithium product to date?
They had another RS 5 yrs ago for 10-1?
Just doing DD here. Still looking at it post RS possibly. Have some play money to drop on something cheap.
nvm, just saw the 20-1 r/s and AS increase.
Sorry for the intrusion
Been Checking this one out. Pros and Cons of the stock?
Great info...Thanks so much. Love to see Sandy and the rest of his scammers get lots of time in prison. He deserves it!
Good News? Yes, Sandy Winick is still in jail.
Vapor land just like that land for their "project" in the Catskills. I must say, those Catskills are a BIG attraction. LOL yeah maybe back in the 50s-70s! Why did they drop SIIR with all those MANY accolades and great mid-western premiere. LOLOL Maybe after this real estate nonsense fades away, they will become a book publisher to publish all of those NY Times Best sellers that he is writing now. LOLOL